Source: LaPress.ca
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Theratechnologies (TH) has announced preclinical findings for its peptide-drug conjugate TH1902 for the treatment of metastatic cancers
  • The new preclinical in vivo findings demonstrate that TH1902 has better anti-metastatic activity when compared to docetaxel alone
  • The drug was administered at an equimolar concentration in a lung metastasis cancer model expressing the sortilin receptor
  • The company intends to present its findings at an upcoming scientific meeting
  • Theratechnologies is a biopharmaceutical company focused on therapies addressing unmet medical needs
  • Theratechnologies (TH) is up by 2.4 per cent and is currently trading at $4.69 per share

Theratechnologies (TH) has announced preclinical findings for its peptide-drug conjugate TH1902 for the treatment of metastatic cancers.

Metastasis is a form of cancer that has spread from its original site to a distant site or organ where it grows or metastasizes. It is well-known that the survival rate for metastatic cancer is low.

The new preclinical in vivo findings demonstrate that TH1902 has better anti-metastatic activity when compared to docetaxel alone when administered at an equimolar concentration in a lung metastasis cancer model expressing the sortilin receptor (SORT1).

SORT1 is a receptor that plays a significant role in protein internalization, sorting and trafficking. It is highly expressed in cancer cells compared to healthy tissue making it an attractive target for cancer drug development.

Additionally, in preclinical models, the company’s SORT1+ technology has been shown to bypass the multidrug resistance protein 1 and inhibit the formation of vasculogenic mimicry, two key resistance mechanisms of chemotherapy treatment.

The company intends to present its findings at an upcoming scientific meeting.

Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer of Theratechnologies, commented,

“These new results are very encouraging for the development of TH1902 in SORT1+ cancers. It is known that SORT1-receptor expression increases as cancers progress and these new data confirm that by targeting the SORT1 receptor, TH1902 could potentially be effective in the treatment of metastasis.

Most importantly, these preclinical findings, if confirmed in humans, are promising signs that we may finally be able to inhibit hard-to-treat cancers with a more effective and better-tolerated treatment.”

The company will host a webcast today at 11:00 am ET to discuss its SORT1+ technology and TH1902. The archived webcast will be available on the company’s website.

Theratechnologies is a biopharmaceutical company focused on therapies addressing unmet medical needs.

Theratechnologies (TH) is up by 2.4 per cent and is currently trading at $4.69 per share as of 10:20 am ET.

More From The Market Herald

" Hemostemix (TSXV:HEM) announces non-brokered private placement

Hemostemix (HEM) has announced a non-brokered private placement of up to 15 million units.
WELL Health - Chairman & CEO Hamed Shahbazi

" WELL Health (TSX:WELL) closes $34.5M public offering

WELL Health Technologies Corp. (WELL) has completed a bought deal public offering for proceeds of $34.5 million.

" Simply Better Brands (TSXV:SBBC) enters the weight loss category

Simply Better Brands (SBBC) has launched its entry into the weight loss category with a PureKana Keto Gummy.

" Cardiol Therapeutics (TSX:CRDL) appoints new directors

Cardiol Therapeutics (CRDL) has appointed Teri Loxam and Chris Waddick to its Board of Directors, effective immediately.